Introduction to SLC8A1-AS1 (G100128590)
Introduction to SLC8A1-AS1
SLC8A1-AS1, also known as SLC8A1 antisense RNA 1, is a long non-coding RNA (lncRNA) that has recently emerged as a potential drug target and biomarker for various diseases. In this article, we will explore the role of SLC8A1-AS1 in disease progression, its potential as a therapeutic target, and its significance as a biomarker for diagnosis and prognosis.
Discovery and Characterization:
SLC8A1-AS1 was first identified as an antisense transcript of the SLC8A1 gene, which encodes the sodium/calcium exchanger 1 protein. It is located on chromosome 2q24.3 and spans over 1.5 kilobases. Initial studies revealed that SLC8A1-AS1 is a conserved lncRNA, suggesting its functional importance in cellular processes.
Role in Disease:
SLC8A1-AS1 has been implicated in various diseases, including cancer, cardiovascular diseases, and neurological disorders. Its dysregulation has been observed in several tumor types, such as breast, pancreatic, and gastric cancers, where it has been shown to promote tumor growth and metastasis.
In cardiovascular diseases, SLC8A1-AS1 has been found to be upregulated in response to various stressors, such as ischemia-reperfusion injury and oxidative stress. It has been suggested to contribute to the development of cardiac hypertrophy and heart failure by modulating the expression of genes involved in calcium handling and mitochondrial function.
Moreover, SLC8A1-AS1 has also been implicated in the pathogenesis of neurodegenerative disorders. It has been shown to interact with microRNAs involved in the regulation of neuronal survival and synaptic plasticity, suggesting its potential role in disease progression.
Potential as a Therapeutic Target:
Given its dysregulation in various diseases, SLC8A1-AS1 has gained attention as a potential therapeutic target. Several studies have attempted to silence or inhibit its expression using antisense oligonucleotides or small interfering RNAs (siRNAs). These approaches have demonstrated promising results in preclinical models, leading to the inhibition of tumor growth, improvement of cardiac function, and attenuation of neurodegenerative processes.
However, further research is required to optimize the delivery systems and evaluate the long-term effects of targeting SLC8A1-AS1. Additionally, the development of small molecules that can modulate its expression or inhibit its function could enhance its potential as a therapeutic target.
Significance as a Biomarker:
SLC8A1-AS1 has shown considerable potential as a biomarker for disease diagnosis and prognosis. Its expression levels have been found to be dysregulated in various biofluids, including blood, serum, and urine, making it accessible for non-invasive testing.
In cancer, SLC8A1-AS1 expression levels have been associated with tumor stage, metastasis, and patient survival. Furthermore, it has been proposed as a predictive biomarker for treatment response, allowing for personalized therapeutic strategies.
In cardiovascular diseases, SLC8A1-AS1 levels have been correlated with disease severity, cardiac function, and adverse outcomes. Monitoring its expression could aid in the early detection of cardiovascular complications and guide treatment decisions.
Similarly, in neurodegenerative disorders, SLC8A1-AS1 has shown potential as a diagnostic and prognostic biomarker. Its levels have been found to be altered in the cerebrospinal fluid and peripheral blood of patients, suggesting its utility in disease monitoring and progression assessment.
SLC8A1-AS1, a lncRNA derived from the SLC8A1 gene, has emerged as a promising drug target and biomarker for various diseases. Its dysregulation has been implicated in cancer progression, cardiovascular diseases, and neurodegenerative disorders. Targeting SLC8A1-AS1 could offer novel therapeutic strategies, while its expression levels have the potential to serve as valuable biomarkers for disease diagnosis, prognosis, and treatment response. Continued research into the molecular mechanisms and clinical applications of SLC8A1-AS1 is essential for harnessing its full therapeutic potential and translating it into clinical practice.
Protein Name: SLC8A1 Antisense RNA 1
More Common Targets
A2M | A2MP1 | A4GALT | ABAT | ABCA1 | ABCB1 | ABCB6 | ABCC5 | ABCC9 | ABCF2 | ABCG2 | ABHD11-AS1 | ABHD3 | ABI1 | ABI2 | ACAA1 | ACACA | ACAN | ACE | ACE2 | ACE3P | ACOT8 | ACP5 | ACSF3 | ACTA2-AS1 | ACTBP12 | ACTG1P12 | ACTG1P22 | ACTL10 | ACTN1-DT | ACTR1A | ACTR1B | ACTR2 | ACTR3 | ACVR2B-AS1 | ADA | ADAD2 | ADAL | ADAM1B | ADAM22 | ADAM8 | ADAMTS15 | ADAMTS16 | ADAMTS17 | ADAMTS18 | ADAMTS19 | ADAMTS9-AS2 | ADAMTSL4 | ADCY4 | ADD1 | ADD2 | ADD3 | ADD3-AS1 | ADGRA3 | ADGRE2 | ADGRF3 | ADGRG2 | ADGRL1-AS1 | ADIPOQ-AS1 | ADM5 | ADPGK-AS1 | AEBP1 | AFF1-AS1 | AFG3L1P | AFM | AFP | AFTPH | AGA | AGAP1-IT1 | AGAP11 | AGAP2-AS1 | AGAP4 | AGER | AGL | AGO3 | AGO4 | AGRP | AGT | AGTR1 | AGTR2 | AGXT | AHCY | AHI1 | AHR | AIF1 | AK6P1 | AKAP9 | AKR1C1 | AKR1C2 | AKT1 | AKT3 | ALDH1L1-AS1 | ALG14 | ALK | ALKBH4 | ALMS1-IT1 | ALOX12-AS1 | ALOX15P1 | AMN1 | ANAPC16 | ANAPC1P1 | ANKFN1 | ANKIB1 | ANKRD16 | ANKRD20A12P | ANKRD20A13P | ANKRD20A17P | ANKRD22 | ANKRD24 | ANKRD26P3 | ANKRD49 | ANKRD61 | ANKRD63 | ANKRD66 | ANLN | ANO6 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2 | ANXA2P3 | ANXA3 | ANXA4 | ANXA5 | ANXA6 | ANXA7 | AOAH | AP1B1 | AP1G1 | AP1M2 | AP1S1 | AP2A2 | AP2B1 | AP2M1 | AP2S1 | AP3S1 | AP4B1-AS1 | APBB1IP | APCDD1L | APELA | APLNR | APOBEC3A_B | APOBEC3B-AS1 | APOBEC3H | APOC4-APOC2 | APOOP2 | APPAT | APTR | AR | ARAP1-AS2 | ARFRP1 | ARHGAP19-SLIT1 | ARHGAP22-IT1 | ARHGAP26-AS1 | ARHGAP26-IT1 | ARHGAP31-AS1 | ARHGEF26-AS1 | ARHGEF33 | ARHGEF38 | ARHGEF38-IT1 | ARHGEF7-AS1 | ARID2 | ARID3A | ARL14EP | ARL15 | ARL17B | ARL2-SNX15 | ARL4A | ARL4C | ARLNC1 | ARMCX4 | ARMCX5-GPRASP2 | ARMCX6 | ARPC1B | ARPC2 | ARPC3 | ARPC4 | ARPC4-TTLL3 | ARPC5 | ARPIN-AP3S2 | ARRDC3-AS1 | ARX | ASAP1-IT2 | ASNSD1 | ASPN | ASTN2-AS1 | ASXL1 | ATAD2B | ATE1-AS1 | ATF4P4 | ATM | ATN1 | ATP11A-AS1 | ATP13A5-AS1 | ATP2A1-AS1 | ATP5PBP5 | ATP5PO | ATP6AP1 | ATP6AP2 | ATP6V0A1 | ATP6V0B | ATP6V0CP1 | ATP6V0E1P1 | ATP6V1FNB | ATP6V1G2 | ATP6V1G2-DDX39B | ATP7A | ATP7B | ATP8B1-AS1 | ATP9A | ATR | ATRX | B3GALT9 | B3GNT6 | BAALC-AS1 | BABAM2-AS1 | BACE1-AS | BANCR | BAX | BBS12 | BCAP31 | BCAR3-AS1 | BCAS2P2 | BCAS3 | BCL11A | BCL2 | BCL2L1 | BCL2L10 | BCL2L11 | BCL2L2-PABPN1 | BCO1 | BCRP7 | BECN1 | BEST2 | BHLHA15 | BHLHE40-AS1 | BICRA | BIVM | BIVM-ERCC5 | BLACAT1 | BLOC1S1-RDH5 | BLOC1S5-TXNDC5 | BMPER | BMPR1B-DT | BMS1P17 | BMS1P21 | BMS1P7 | BNC2 | BOK-AS1 | BOLA3-DT | BORCS5 | BORCS6 | BORCS7 | BORCS7-ASMT | BPIFB5P | BRAF | BRCA1 | BRINP1 | BRWD1 | BSN-DT | BSPH1 | BSPRY | BTBD1 | BTBD16 | BTG4 | BTN2A3P | BTNL10P | BYSL | C10orf71 | C10orf71-AS1 | C10orf90 | C10orf95-AS1 | C11orf24 | C11orf71 | C11orf91 | C13orf46 | C16orf82 | C16orf95 | C17orf107 | C17orf99 | C18orf54 | C1orf68 | C1QBP | C1QL2 | C1QTNF1-AS1 | C1QTNF3-AMACR | C20orf181 | C21orf58 | C21orf62-AS1 | C21orf91 | C2CD4D | C2CD4D-AS1 | C4B_2 | C4orf46P3 | C5orf52